Send to

Choose Destination
See comment in PubMed Commons below
J Diabetes Sci Technol. 2008 May;2(3):384-91.

Safety and effectiveness of a computerized subcutaneous insulin program to treat inpatient hyperglycemia.

Author information

Division of Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.



This proof of concept study was designed to evaluate the safety and effectiveness of a computerized insulin program, the Clarian GlucoStabilizer Subcutaneous Insulin Program (CGS-SQ). This paper discusses the CGS-SQ's impact on the glycemic control of hospitalized patients with hyperglycemia.


Patients at Methodist and Indiana University Hospitals requiring subcutaneous insulin were treated using the CGS-SQ. This program calculates subcutaneous bolus insulin doses based on the current blood glucose (BG), using an insulin sensitivity factor, the number of grams of carbohydrates eaten, and an insulin-to-carbohydrate ratio, with a goal of maintaining the patient's BG in a prespecified target range. The target range, insulin sensitivity factor, and insulin-to-carbohydrate ratio are established by the physician.


From April 2006 to September 2007, the CGS-SQ treated 1772 patients at Methodist and Indiana University Hospitals, with 46,575 BGs in its database. For these patients, the average BG was 158.3 mg/dl, 40.5% percent of BGs were in the default target range of 100-150 mg/dl, and 69.8% were in the wider range of 70-180 mg/dl. The hypoglycemia (BG <40 mg/dl) rate was 0.18%.


The CGS-SQ provided a means to deliver insulin in a standardized manner, resulting in satisfactory BG control with a low hypoglycemia rate, thus serving as a tool for safe and effective insulin therapy for hospitalized patients.


computers; diabetes; dosing; hyperglycemia; insulin; protocol; subcutaneous

PubMed Commons home

PubMed Commons


    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center